Pliant Therapeutics Prepares for Major Respiratory Congress
Pliant Therapeutics Announces Upcoming Presentations
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a leader in developing novel therapeutics for fibrotic diseases, has announced four significant presentations at the European Respiratory Society (ERS) International Congress 2024. This event will be held in Vienna, showcasing groundbreaking research in respiratory health and treatment options.
Presentation Details
Late Breaker – Oral and ePoster Presentations
The first presentation will focus on evaluating the antifibrotic activity of bexotegrast, a dual ?V?6/?V?1 integrin inhibitor. This study, presented by Dr. Martin Decaris from Pliant Therapeutics, examines the effect of bexotegrast using precision cut-lung slices derived from non-IPF interstitial lung disease explants. The session is scheduled for September 8, with a focus on new insights into sarcoidosis.
Later Breaker – Oral and ePoster Presentations
Another compelling presentation will cover the impact of bexotegrast on type 1 collagen deposition in idiopathic pulmonary fibrosis (IPF) patients after 12 weeks of therapy. Dr. Sydney B. Montesi from Massachusetts General Hospital will present this important research as part of a session dedicated to advances in clinical practice for rare interstitial diseases.
Safety and Tolerability of Bexotegrast
Oral and Poster Presentations
Pliant Therapeutics will also share findings from Phase 2 trials on the safety and tolerability of bexotegrast in patients with IPF and primary sclerosing cholangitis (PSC). Dr. Gregory Cosgrove from the company will lead this presentation on September 9, discussing novel management strategies that could reshape treatment for pulmonary fibrosis.
Poster Presentation on Biomarkers
Additionally, a poster presentation will focus on post-hoc biomarker analysis in IPF participants receiving bexotegrast over a 12-week period. Dr. Martin Decaris will deliver insights on this analysis during the session on the pathogenesis of pulmonary fibrosis and serum biomarkers on September 10.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is dedicated to the discovery and development of treatments for fibrotic diseases. Its lead product candidate, bexotegrast (PLN-74809), aims to provide innovative solutions for conditions such as IPF and PSC. The company has achieved Fast Track Designation and Orphan Drug Designation from the U.S. FDA for these conditions. Furthermore, Pliant has initiated the BEACON-IPF trial, a pivotal Phase 2b/3 trial exploring the efficacy of bexotegrast.
As part of its clinical advancements, Pliant is also progressing with PLN-101095, a new small molecule aimed at targeting solid tumors, and has regulatory clearance for a Phase 1 study of PLN-101325, which focuses on muscular dystrophies.
Contact Information
For more information, please visit Pliant Therapeutics' website. Investor and media inquiries can be directed to Christopher Keenan, Vice President of Investor Relations and Corporate Communications at Pliant Therapeutics, Inc. via email at ir@pliantrx.com.
Frequently Asked Questions
What is the focus of the upcoming presentations by Pliant Therapeutics?
The presentations will cover innovative research on the antifibrotic activity of bexotegrast, a treatment for fibrotic diseases.
When will the European Respiratory Society International Congress take place?
The congress will take place from September 7 to September 11, 2024.
Where can I find more information about Pliant Therapeutics?
More information can be found on Pliant Therapeutics' official website.
What is bexotegrast?
Bexotegrast is Pliant's lead product candidate, designed as a dual selective inhibitor targeting integrins associated with fibrotic diseases.
Who should contact Pliant Therapeutics for investor inquiries?
Investor inquiries should be directed to Christopher Keenan, Vice President of Investor Relations and Corporate Communications.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Advanced Digital Twin Solutions Projected to Transform Logistics
- BlackRock Adjusts Shareholding in Novonesis for Growth Strategy
- Revamping Expectations: AngioDynamics Prepares for Earnings Release
- SAP and Carahsoft Face Major Legal Challenges Amid Investigation
- BofA Adjusts STMicroelectronics Forecast Amid Market Challenges
- Optimistic Forecast for JSW Steel Amid Capacity Expansion Plans
- ASEAN+3 Growth Forecasts Highlight Resilience in Economy
- Stora Enso Strategizes Divestment of Forest Assets
- Market Reactions to Middle East Conflict and Tesco's Strong Performance
- Mentimeter Selected as Key Tool for Engaging at SXSW 2024
Recent Articles
- Alvotech Joins Morgan Stanley Global Healthcare Conference
- Alvotech to Join Morgan Stanley Global Healthcare Conference
- Exploration Update from Westhaven Gold at Shovelnose
- Diana Shipping Inc. Secures Charter Contract for m/v G. P. Zafirakis
- Micheal J. Burt Joins Healthcare Integrated Technologies Board
- Nvidia's Investment Potential: Analyzing Market Trends
- Qualcomm to Acquire Sequans' 4G IoT Technology
- Market Reactions Ahead of Nvidia Earnings and Rate Cuts
- Maximizing Your Retirement Savings with Financial Strategies
- Warren Buffett's Latest Investment in Ulta Beauty
- Top Dividend Stocks for Passive Income Success
- Professional Diversity Network Rebrands to TalentAlly
- Professional Diversity Network Launches TalentAlly Job Board
- Great Lakes Secures $256.2 Million in Dredging Projects
- Great Lakes Secures $256.2 Million in New Dredging Projects
- Urbo Bankas Reports Strong Growth in 2024 Financial Results
- Kauno energija AB Reports Strong Financial Growth for 2024
- ParaZero Showcases Drone Safety Systems at Major Events
- Gerardo King Joins Liberty Star Minerals Board of Directors
- Haivision and Shield AI Unite for Advanced Defense Solutions
- Brilliant Earth Elevates Executives for Growth and Excellence
- Mike Fenger Joins Zoom's Board of Directors
- Capital Clean Energy Carriers Corp. Completes Corporate Conversion
- Stran Strengthens Market Position with Strategic Acquisition
- Aquafil SpA Promotes Circular Design for Sustainable Future
- Top Kingwin Ltd Launches AI Hardware Subsidiary for Future Tech
- noco-noco Inc Secures Temporary Listing Exception on Nasdaq
- Dr. Belgacem Haba's Impact on the Semiconductor Revolution
- Firefly Neuroscience CEO to Present at Global Investment Conference
- Positron Corporation Sells NeuSight PET-CT Scanner
- Optinose to Showcase Innovations at Global Investment Conference
- UFP Technologies to Present at Midwest IDEAS Investor Conference
- TIC Market Forecast: Growth and Key Players Overview
- LPL Financial Welcomes Financial Advisor Kelly Compton
- Growing Sharps Containers Market Expected to Reach USD 776.18 Million
- NevGold Secures Financing of Unsecured Convertible Securities
- Hamilton Thorne Prepares for Special Shareholder Meeting
- 5E Advanced Materials Launches $4.0 Million Offering
- Wearable Devices Enhances Mudra Band for Apple Watch Control
- Pocket Printer Market Expected to Reach $3.47 Billion
- AITX's RAD Achieves Positive Cash Flow Milestone
- SHEIN Launches Street-Style Pop-Up at Canadian National Exhibition
- Ready to Drink Tea & Coffee Market Growth Insights
- Ready-to-Drink Tea and Coffee Market Growth Insights
- Growth in Plant-Based Pet Food Market Driven by Innovation
- Prescriptive Analytics Market Growth Insights
- Smart Airport Market Growth Forecast to USD 92 Billion
- Sterility Testing Market Growth: Key Insights and Projections
- CAR-T Cell Funding Market Trends and Future Growth Analysis
- AB International Group Announces Stock Repurchase Plans